UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004468
Receipt number R000005338
Scientific Title Phase I/II study of gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancer
Date of disclosure of the study information 2010/11/14
Last modified on 2020/01/28 09:04:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I/II study of gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancer

Acronym

gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancer

Scientific Title

Phase I/II study of gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancer

Scientific Title:Acronym

gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancer

Region

Japan


Condition

Condition

Patients with advanced biliary tract cancer that was not amenable to potentially curative surgery or that had recurred after surgery

Classification by specialty

Hepato-biliary-pancreatic medicine Hematology and clinical oncology Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to evaluate the safety of GCS therapy for phase I and efficacy of GCS therapy for phase II.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase I,II


Assessment

Primary outcomes

Phase I
Safety
Phase II
Overall Survival

Key secondary outcomes

Phase II
Toxicity and response rate


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeasted every 2 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients with cytologically or histologically proved biliary tract cancer
2. age >=20 years
3. PS 0-2
4. No prior history of chemotherapy or radiotherapy. Patients who has undergone adjuvant chemotherapy are eligible if at least 6 months has passed since the last administration.
5. Adequate bone marrow function (neutrophil count >=1,500/mm3, and platelet count >=100,000/mm3), liver function (total bilirubin >=3 mg/dL and AST/ALT >=150 IU/L), and renal function (creatinine clearance >=60 mL/min)
6.No other serious comorbid disease
7.Adequate oral intake
8.Provided written informed consent

Key exclusion criteria

1. Patients with interstitial pneumonia or pulmonary fibrosis
2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months
3. Patients with severe active infection
4. Patients who are pregnant or lactating, or have an intention to get pregnant
5. Patients with a history of severe drug allergy
6. Patients with other serious comorbid disease
7. Patients with mental disease
8. Patients who are judged inappropriate for the entry into the study by the principle doctor
9. Patients with watery diarrhea

Target sample size

55


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Etsuro Hatano

Organization

Kyoto University Hospital

Division name

Department of Surgery, Graduate School of Medicine

Zip code


Address

54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto

TEL

075-751-4349

Email

etsu@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masashi Kanai

Organization

Kyoto University Hospital

Division name

Department of Clinical Oncology and Pharmacogenomics

Zip code


Address

54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto

TEL

075-751-4349

Homepage URL


Email

kanai@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Kansai Hepatobiliary Oncology Group

Institute

Department

Personal name



Funding Source

Organization

Osaka Medical Center for Cancer and Cardiovascular Diseases

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 11 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2010 Year 10 Month 18 Day

Date of IRB

2010 Year 10 Month 18 Day

Anticipated trial start date

2010 Year 12 Month 01 Day

Last follow-up date

2013 Year 11 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 10 Month 28 Day

Last modified on

2020 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005338


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name